MARKET

MTFB

MTFB

Motif Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1050
0.0000
0.00%
Delisted 09:30 03/27 EDT
OPEN
--
PREV CLOSE
0.1101
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
11.50
52 WEEK LOW
0.0750
MARKET CAP
50.97M
P/E (TTM)
-2.6451
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MTFB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MTFB stock price target is 3.500 with a high estimate of 5.00 and a low estimate of 2.000.

EPS

MTFB News

More
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters · 12/06/2019 03:03
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters · 12/05/2019 20:32
  • Hedge fund titan Steve Cohen in talks to increase his stake in Mets
  • CNBC.com · 12/04/2019 20:44
  • Mayor Pete is Hollywood's top pick now that Kamala Harris is out of the presidential race
  • CNBC.com · 12/04/2019 13:15

Industry

Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About MTFB

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.
More

Webull offers kinds of Motif Bio PLC stock information, including NASDAQ:MTFB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTFB stock news, and many more online research tools to help you make informed decisions.